Compound Profile
Epithalon's Record Runs From Cell Culture to Rhesus Monkeys
Published: August 25, 2026
TL;DR
Epithalon is known for telomere findings, and those findings come from cell culture. A 2003 experiment added the peptide to telomerase-negative human fetal fibroblasts, which then showed telomerase activity and longer telomeres. A 2025 study reproduced the lengthening in normal epithelial and fibroblast cells through telomerase upregulation, and found a different route in breast-cancer lines: alternative lengthening of telomeres. Above the cell level the record is two experiments, a rat colon-carcinogenesis model and an endocrine study in aged rhesus monkeys. In July 2026 FDA's compounding advisory committee voted 7 to 4, with one abstention, to recommend it for the 503A bulks list. The nominated use was insomnia.
Curo lists this material as Epithalon 10 mg, one entry in the research peptide catalogue. Lot documents are searchable through the COA library, and catalogue materials are supplied for research use only.
The telomere record begins in cultured human cells
The famous part of Epithalon's research record begins in a laboratory dish. In 2003, investigators added the peptide to telomerase-negative human fetal fibroblasts and reported three things in sequence: expression of the telomerase catalytic subunit, measurable telomerase activity, and telomere elongation. The cells were human. The experiment was not. The 2003 fetal-fibroblast paper is a cell-culture result.
That ordering is worth keeping. Expression of the catalytic component came first, then enzyme activity, then a change in length. Named that way, the finding carries its own cell type, setting, and measurements, which is a good deal more informative than the telomere headline it usually gets compressed into.
A 2025 study widened that cell-culture record. Epitalon exposure was associated with dose-dependent telomere-length extension and hTERT or telomerase upregulation in normal epithelial and fibroblast cells. In breast-cancer cell lines, the investigators also observed activation of alternative lengthening of telomeres, or ALT. ALT is another cellular route for maintaining telomeres, separate from telomerase upregulation. The 2025 cell-line study therefore reported different responses across normal and breast-cancer cell systems, rather than one universal mechanism.
The compound travels under four names, so the trial registry has to be checked under all of them. ClinicalTrials.gov searches for epitalon, epithalon, epithalone, and AEDG each returned zero studies on August 25, 2026. Under those four labels the registry holds no NCT identifier, phase, sponsor, enrolment figure, or posted result.
Rats and rhesus monkeys supplied the organism-level data
Above the dish, two experiments carry the record. A 2002 study put 80 rats into a 1,2-dimethylhydrazine-induced colon carcinogenesis model, counted total colon tumors per rat, and found fewer of them in two Epitalon groups than in the saline controls. The 80-rat study is a tumor-count result inside an induced model, and it stops there.
The 2005 primate study asked something else entirely. Researchers administered Epitalon to old rhesus monkeys and measured basal glucose, insulin, nighttime melatonin, and responses during glucose-tolerance testing. The rhesus-monkey paper reports changes in those endocrine and metabolic measures. Its protocol was built for old monkeys, and nothing in the published record converts it into a human protocol.
So the organism-level evidence comes down to two specific things: tumor counts in an induced rat carcinogenesis model, and glucose, insulin, melatonin, and glucose-tolerance responses in aged primates. Neither supplies human pharmacokinetics, a human safety profile, or a lifespan result.
Endpoints are worth reading closely here. A tumor count per rat is not a lifespan measure. A shift in circulating glucose, insulin, or nighttime melatonin is not a statement about aging in general. Each result belongs to its model, its species, and the variable someone chose to measure.
The compounding committee backed it, 7 to 4
A Federal Register notice put Epitalon free base and Epitalon acetate in front of FDA's Pharmacy Compounding Advisory Committee on July 24, 2026, under docket FDA-2025-N-6895. The use evaluated for the Section 503A Bulks List nomination was insomnia, which tends to surprise anyone arriving from the longevity literature.
FDA's own staff argued against listing. The agency's briefing document for Epitalon reported no human safety data, particularly for subcutaneous use, and no evidence supporting effectiveness for insomnia. The committee went the other way. It voted separately on each form and recommended both for inclusion, 7 in favor to 4 against with one abstention. Hyman, Phelps & McNamara recorded the day's votes, and McDermott Will & Schulte published a tally table carrying the same figures.
The practical effect is smaller than the headline. A committee recommendation is advisory and FDA is not bound by it. Nothing reaches the 503A list without agency rulemaking, and Epitalon is not on that list today. FDA's meeting page carries the briefing documents, the questions put to the committee and the archived broadcast. It carries no minutes and no vote table, so the tallies above rest on contemporaneous reporting rather than an FDA document.
Two neighbouring compounds have a record shaped much the same way. Semax is another Russian-developed peptide with a long home literature, an empty US registry, and its own slot on the July 2026 agenda. Selank comes from the same research lineage and has been examined in anxiety and cytokine work.
Four labels lead back to a sequence and identifiers
Spelling drifts, so identifiers do the work instead. The PubChem entry lists Epitalon, Epithalon, and Epithalone among the names for CID 219042, along with CAS Registry Number 307297-39-8. The 2020 AEDG paper gives the tetrapeptide sequence as Ala-Glu-Asp-Gly. FDA's UNII record files EPITALON as ingredient substance O65P17785G. Those anchors hold when a label's spelling does not.
An identity check runs on two layers. At the compound layer, reconcile whatever spelling appears against AEDG, the full sequence, the CAS number, and the UNII. At the batch layer, reconcile the product and lot printed on the material against the batch document posted for it. Curo's guide to verifying a lot certificate covers the document-level check, and the quality and testing standard covers what each method reports.
Keeping the two layers separate is the point. A correct-looking record for one spelling, or for a different lot, is easy to mistake for evidence about the vial in front of you.
The 10 mg on the label belongs in its own lane. It is the size of Curo's catalogue variant. It is not a research protocol, a human dose, or a pharmacokinetic value, and no human half-life for this compound appears anywhere in the published literature.
Common questions
Does Epithalon lengthen telomeres in people?
The cited telomere results come from cultured human cells. They establish cellular telomerase and telomere observations, including ALT activation in breast-cancer lines, but no telomere-length result in living people.
Why does the ALT finding matter when reading the 2025 study?
The study observed telomerase upregulation in normal epithelial and fibroblast cells and ALT activation in breast-cancer lines. The result depends on the cell system, so the headline "telomere extension" does not describe one shared cellular route.
What did the animal studies actually measure?
The rat experiment counted colon tumors in an induced carcinogenesis model. The rhesus-monkey experiment measured basal glucose, insulin, nighttime melatonin, and glucose-tolerance responses in old animals.
How can I check whether Epitalon, Epithalon, Epithalone, or AEDG is the intended material?
Use the sequence and formal identifiers in the identity section, then reconcile the product name and lot across the listing, label, and batch document. Do not rely on spelling alone or use a generic certificate in place of a lot-specific record.